Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Descriptive, Post-Marketing, Passive Surveillance Safety Study of Menactra Vaccine
This study is enrolling participants by invitation only.
Sponsored by: Sanofi-Aventis
Information provided by: Sanofi-Aventis
ClinicalTrials.gov Identifier: NCT00254995
  Purpose

To further characterize the vaccine safety profile and to identify any signals of potentially vaccine-related AEs not detected during pre-licensure studies.


Condition Intervention Phase
Meningitis
Biological: None administered in this study
Phase IV

MedlinePlus related topics: Meningitis
Drug Information available for: Meningococcal Vaccines
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort
Official Title: Post-Licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra ™)

Further study details as provided by Sanofi-Aventis:

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 20000
Study Start Date: July 2005
Estimated Study Completion Date: December 2008
Groups/Cohorts Assigned Interventions
1 Biological: None administered in this study
N/A in this study

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Past receipt of Menactra vaccine

Criteria

Inclusion Criteria:

  • Receipt of Menactra vaccine during the study period.

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00254995

Locations
United States, California
Oakland, California, United States, 94612
Sponsors and Collaborators
Sanofi-Aventis
Investigators
Study Director: Clinical Trials sanofi pasteur
  More Information

Related Info  This link exits the ClinicalTrials.gov site
Related Info  This link exits the ClinicalTrials.gov site

Responsible Party: Sanofi Pasteur, Inc. ( Medical Monitor )
Study ID Numbers: MTA30, MTA30
Study First Received: November 15, 2005
Last Updated: February 12, 2008
ClinicalTrials.gov Identifier: NCT00254995  
Health Authority: United States: Food and Drug Administration

Keywords provided by Sanofi-Aventis:
Meningitis,
Meningococcal

Study placed in the following topic categories:
Central Nervous System Infections
Central Nervous System Diseases
Diphtheria
Meningitis

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009